Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein–Barr Virus–Positive Nasopharyngeal Carcinoma

IFN-γ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade

(2019) Maria Pia Pistillo et al.   Cellular & Molecular Immunology

The host protecting the tumor from the host — targeting PD‑L1 expressed by host cells

(2018) David H. Munn   JOURNAL OF CLINICAL INVESTIGATION

Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study

(2018) Qiu-Yan Chen et al.   Cancer Research and Treatment

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

(2018) Kristina Buder-Bakhaya et al.   Frontiers in Immunology

The addition of pretreatment plasma Epstein-Barr virus DNA into the 8th edition of nasopharyngeal cancer TNM stage classification

(2018) Victor Ho-Fun Lee et al.   INTERNATIONAL JOURNAL OF CANCER

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

(2018) Wenfeng Fang et al.   LANCET ONCOLOGY

Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality

(2018) Sara R. Selitsky et al.   mSystems

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

(2018) Jun Tang et al.   NATURE REVIEWS DRUG DISCOVERY

EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression

(2018) Tian Xue et al.   PATHOLOGY

Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer

(2017) K.C. Allen Chan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epstein–Barr virus infection and nasopharyngeal carcinoma

(2017) Sai Wah Tsao et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT)

(2017) Ya-bin Jin et al.   PLoS One

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients

(2017) Xiaofang Xing et al.   OncoImmunology

Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma

(2016) Nghia Nguyen et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Nasopharyngeal carcinoma

(2016) Melvin L K Chua et al.   LANCET

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications

(2016) Ruri Saito et al.   MODERN PATHOLOGY

Comparison of (18)F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis

(2016) Junbao Wei et al.   ORAL ONCOLOGY

Prognostic utility of 18F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker site

(2016) Peter Lin et al.   RADIOTHERAPY AND ONCOLOGY

Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective

(2015) Anne W.M. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma

(2015) Jianwei Zhang et al.   MEDICAL ONCOLOGY

Nasopharyngeal Carcinoma

(2015) Sophia C. Kamran et al.   Surgical Oncology Clinics of North America

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment

(2013) M. Adham et al.   CLINICAL CANCER RESEARCH

Determining EBV load: current best practice and future requirements

(2013) Stephanie Ruf et al.   Expert Review of Clinical Immunology